marketcaparena
Search

    GKOS

    GLAUKOS Corp

    Company overview

    Market capitalization
    $9.35B
    Employees
    1,094
    Latest publication
    2026-09-29
    About GLAUKOS Corp

    Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20222022-03-31 · USDQ3 20212021-09-30 · USDQ4 20182018-12-31 · USDQ4 20172017-12-31 · USDQ3 20172017-09-30 · USDQ1 20172017-03-31 · USDQ4 20162016-12-31 · USD
    Total Revenue185,610,000USD67,681,000USD74,710,000USD54,076,000USD41,650,000USD40,412,000USD35,907,000USD33,172,000USD
    Cost Of Revenue34,016,000USD17,063,000USD15,370,000USD7,118,000USD4,630,000USD5,718,000USD5,180,000USD4,811,000USD
    Gross Profit151,594,000USD50,618,000USD59,340,000USD46,958,000USD37,020,000USD34,694,000USD30,727,000USD28,361,000USD
    Research Development51,301,000USD26,877,000USD28,846,000USD12,957,000USD10,525,000USD9,805,000USD8,942,000USD7,399,000USD
    Selling General Administrative116,060,000USD43,949,000USD44,470,000USD30,304,000USD23,863,000USD24,141,000USD21,481,000USD18,894,000USD
    Total Operating Expenses168,861,000USD40,826,000USD48,316,000USD45,061,000USD36,488,000USD33,946,000USD30,423,000USD27,893,000USD
    Operating Income-17,267,000USD9,792,000USD11,024,000USD1,897,000USD532,000USD748,000USD304,000USD468,000USD
    Total Other Income Expense Net-454,000USD-4,089,000USD-4,592,000USD412,000USD437,000USD630,000USD629,000USD-431,000USD
    Interest Expense1,459,000USD3,416,000USD3,413,000USD8,000USD3,000USD28,000USD7,000USD696,000USD
    Income Before Tax-17,721,000USD5,703,000USD6,432,000USD2,309,000USD969,000USD1,378,000USD933,000USD37,000USD
    Income Tax Expense656,000USD326,000USD202,000USD530,000USD-37,000USD53,000USD55,000USD-97,000USD
    Net Income-18,377,000USD5,377,000USD6,230,000USD1,779,000USD1,006,000USD1,325,000USD878,000USD134,000USD
    Unclassified Operating Expenses—-30,000,000USD-25,000,000USD—————
    Interest Income—287,000USD291,000USD—————
    Net Interest Income—-3,129,000USD-3,122,000USD—————
    Tax Provision—326,000USD202,000USD—————
    Net Income From Continuing Ops—5,377,000USD6,230,000USD1,779,000USD1,006,000USD1,325,000USD878,000USD134,000USD
    Ebit—9,119,000USD9,845,000USD1,897,000USD966,000USD748,000USD940,000USD422,000USD
    Ebitda—18,000,000USD18,467,000USD3,098,000USD2,507,000USD2,261,000USD1,949,000USD1,734,000USD
    Depreciation And Amortization—8,881,000USD8,622,000USD1,201,000USD1,541,000USD1,513,000USD1,009,000USD1,312,000USD
    Reconciled Depreciation—8,881,000USD8,622,000USD1,201,000USD1,541,000USD1,513,000USD1,009,000USD1,312,000USD
    Non Operating Income Net Other—-673,000USD-4,592,000USD-1,240,000USD434,000USD658,000USD636,000USD-46,000USD
    Net Income Applicable To Common Shares—5,377,000USD6,230,000USD1,779,000USD1,006,000USD1,325,000USD878,000USD134,000USD
    Selling And Marketing Expenses———1,800,000USD2,100,000USD——1,600,000USD
    Minority Interest———0USD0USD0USD0USD0USD
    Discontinued Operations———0USD0USD0USD0USD0USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20162016-12-31 · USD
    Total Revenue114,397,000USD
    Cost Of Revenue16,177,000USD
    Gross Profit98,220,000USD
    Research Development29,223,000USD
    Selling General Administrative63,156,000USD
    Selling And Marketing Expenses1,600,000USD
    Total Operating Expenses93,979,000USD
    Operating Income4,241,000USD
    Interest Income889,000USD
    Interest Expense608,000USD
    Net Interest Income281,000USD
    Income Before Tax4,565,000USD
    Income Tax Expense43,000USD
    Tax Provision43,000USD
    Net Income4,522,000USD
    Net Income From Continuing Ops4,522,000USD
    Ebit4,241,000USD
    Ebitda8,963,000USD
    Depreciation And Amortization4,722,000USD
    Total Other Income Expense Net324,000USD
    Non Operating Income Net Other932,000USD
    Net Income Applicable To Common Shares4,522,000USD
    SourceLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets920,521,000USD893,326,000USD893,487,000USD999,378,000USD986,958,000USD966,178,000USD974,756,000USD926,543,000USD
    Cash And Equivalents114,485,000USD———————
    Total Current Assets515,778,000USD485,753,000USD474,984,000USD454,768,000USD436,065,000USD444,544,000USD449,792,000USD397,282,000USD
    Other Current Assets31,346,000USD26,993,000USD24,052,000USD18,509,000USD13,673,000USD14,857,000USD12,455,000USD18,506,000USD
    Total Liabilities238,035,000USD———————
    Total Current Liabilities102,329,000USD89,415,000USD101,275,000USD87,516,000USD79,136,000USD68,529,000USD75,125,000USD71,684,000USD
    Other Current Liabilities83,190,000USD———————
    Other Non Current Liabilities32,429,000USD———————
    Total Stockholder Equity682,486,000USD670,928,000USD656,155,000USD769,543,000USD765,112,000USD763,959,000USD766,931,000USD668,509,000USD
    Total Equity Including Noncontrolling Interest682,486,000USD———————
    Net Receivables138,900,000USD119,691,000USD108,608,000USD98,684,000USD82,985,000USD71,531,000USD60,744,000USD56,408,000USD
    Inventory59,306,000USD62,384,000USD63,564,000USD63,863,000USD64,621,000USD59,460,000USD57,678,000USD59,895,000USD
    Property Plant Equipment Net143,385,000USD182,257,000USD184,184,000USD182,487,000USD184,411,000USD170,199,000USD169,937,000USD168,267,000USD
    Goodwill66,710,000USD———————
    Intangible Assets127,151,000USD133,028,000USD141,916,000USD264,136,000USD270,491,000USD257,869,000USD263,445,000USD269,418,000USD
    Accounts Payable19,139,000USD19,153,000USD24,624,000USD19,883,000USD13,684,000USD15,825,000USD13,026,000USD11,103,000USD
    Common Stock59,000USD58,000USD58,000USD57,000USD57,000USD57,000USD56,000USD55,000USD
    Retained Earnings-971,290,000USD-952,913,000USD-933,130,000USD-799,473,000USD-783,242,000USD-763,585,000USD-745,439,000USD-711,859,000USD
    Accumulated Other Comprehensive Income2,384,000USD2,643,000USD3,303,000USD3,062,000USD2,872,000USD2,605,000USD2,615,000USD2,620,000USD
    Total Liab—222,398,000USD237,332,000USD229,835,000USD221,846,000USD202,219,000USD207,825,000USD258,034,000USD
    Other Current Liab—70,262,000USD76,651,000USD67,633,000USD65,452,000USD52,704,000USD62,099,000USD58,640,000USD
    Capital Stock—58,000USD58,000USD57,000USD57,000USD57,000USD56,000USD55,000USD
    Good Will—66,710,000USD66,710,000USD66,710,000USD66,710,000USD66,134,000USD66,134,000USD66,134,000USD
    Cash—104,249,000USD90,813,000USD98,246,000USD100,813,000USD114,252,000USD169,626,000USD100,143,000USD
    Cash And Short Term Investments—276,685,000USD278,760,000USD273,712,000USD274,786,000USD298,696,000USD318,915,000USD262,473,000USD
    Net Debt—-1,193,000USD48,830,000USD6,069,000USD4,210,000USD-8,772,000USD-66,227,000USD56,984,000USD
    Short Long Term Debt Total—103,056,000USD139,643,000USD104,315,000USD105,023,000USD105,480,000USD103,399,000USD157,127,000USD
    Short Term Investments—172,436,000USD187,947,000USD175,466,000USD173,973,000USD184,444,000USD149,289,000USD162,330,000USD
    Property Plant Equipment Gross—182,257,000USD239,723,000USD182,487,000USD184,411,000USD170,199,000USD214,511,000USD168,267,000USD
    Common Stock Shares Outstanding—58,022,000shares57,506,000shares57,398,000shares57,205,000shares56,637,000shares55,584,000shares55,037,000shares
    Non Current Assets Total—407,573,000USD418,503,000USD544,610,000USD550,893,000USD521,634,000USD586,355,000USD529,261,000USD
    Non Current Liabilities Total—132,983,000USD136,057,000USD142,319,000USD142,710,000USD133,690,000USD132,700,000USD186,350,000USD
    Non Current Liabilities Other—29,486,000USD31,740,000USD31,083,000USD30,777,000USD21,292,000USD22,373,000USD22,080,000USD
    Non Currrent Assets Other—25,578,000USD21,859,000USD27,443,000USD25,447,000USD27,432,000USD86,839,000USD25,442,000USD
    Net Working Capital—396,338,000USD373,709,000USD367,252,000USD356,929,000USD376,015,000USD374,667,000USD325,598,000USD
    Unclassified Non Current Liabilities—103,497,000USD104,317,000USD111,236,000USD111,933,000USD112,398,000USD110,327,000USD107,511,000USD
    Unclassified Equity—1,621,082,000USD1,585,866,000USD1,565,840,000USD1,545,368,000USD1,524,825,000USD1,509,643,000USD1,377,638,000USD
    Other Assets——————-61,391,000USD—
    Long Term Debt———————56,759,000USD
    Unclassified Current Liabilities———————1,941,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets893,487,000USD974,756,000USD940,414,000USD1,074,168,000USD1,128,827,000USD1,005,502,000USD818,400,000USD206,970,000USD
    Intangible Assets141,916,000USD263,445,000USD282,956,000USD307,869,000USD332,781,000USD357,693,000USD382,605,000USD—
    Other Current Assets24,052,000USD12,455,000USD18,194,000USD17,250,000USD15,626,000USD13,206,000USD7,900,000USD8,248,000USD
    Total Liab237,332,000USD207,825,000USD478,648,000USD544,163,000USD541,676,000USD338,053,000USD145,128,000USD33,110,000USD
    Total Stockholder Equity656,155,000USD766,931,000USD461,766,000USD530,005,000USD587,151,000USD667,449,000USD673,272,000USD173,860,000USD
    Other Current Liab76,651,000USD62,099,000USD60,574,000USD57,526,000USD55,017,000USD44,146,000USD51,077,000USD24,079,000USD
    Common Stock58,000USD56,000USD49,000USD48,000USD47,000USD45,000USD44,000USD36,000USD
    Capital Stock58,000USD56,000USD49,000USD48,000USD47,000USD45,000USD44,000USD36,000USD
    Retained Earnings-933,130,000USD-745,439,000USD-599,067,000USD-464,406,000USD-365,211,000USD-310,058,000USD-189,710,000USD-205,134,000USD
    Good Will66,709,999USD66,134,000USD66,134,000USD66,134,000USD66,134,000USD66,134,000USD66,134,000USD—
    Cash90,813,000USD169,626,000USD93,467,000USD119,525,000USD100,708,000USD96,596,000USD62,430,000USD29,821,000USD
    Cash And Short Term Investments278,760,000USD318,915,000USD295,431,000USD352,695,000USD414,051,000USD404,368,000USD173,983,000USD140,488,000USD
    Total Current Assets474,984,000USD449,792,000USD395,461,000USD443,859,000USD486,126,000USD469,442,000USD262,878,000USD176,567,000USD
    Total Current Liabilities101,275,000USD75,125,000USD74,014,000USD72,359,000USD63,360,000USD49,702,000USD57,700,000USD30,365,000USD
    Net Debt48,830,000USD-66,227,000USD290,271,000USD263,382,000USD282,677,000USD175,399,000USD10,200,000USD-29,821,000USD
    Short Long Term Debt Total139,643,000USD103,399,000USD383,738,000USD382,907,000USD383,385,000USD271,995,000USD72,630,000USD—
    Short Term Investments187,947,000USD149,289,000USD201,964,000USD233,170,000USD313,343,000USD307,772,000USD111,553,000USD110,667,000USD
    Net Receivables108,608,000USD60,744,000USD39,850,000USD36,073,000USD33,438,000USD36,059,000USD38,417,000USD18,673,000USD
    Inventory63,564,000USD57,678,000USD41,986,000USD37,841,000USD23,011,000USD15,809,000USD42,578,000USD13,282,000USD
    Accounts Payable24,624,000USD13,026,000USD13,440,000USD14,403,000USD7,333,000USD4,371,000USD5,781,000USD6,286,000USD
    Property Plant Equipment Net184,184,000USD169,937,000USD174,538,000USD166,830,000USD146,133,000USD95,460,000USD91,808,000USD19,153,000USD
    Property Plant Equipment Gross239,723,000USD214,511,000USD209,015,000USD94,403,000USD68,969,000USD95,460,000USD91,808,000USD19,153,000USD
    Accumulated Other Comprehensive Income3,303,000USD2,615,000USD1,165,000USD-2,975,000USD15,000USD1,004,000USD1,330,000USD738,000USD
    Common Stock Shares Outstanding57,190,000shares52,755,000shares48,433,000shares47,444,000shares46,423,000shares44,497,000shares41,145,000shares35,317,000shares
    Non Current Assets Total418,503,000USD524,964,000USD544,953,000USD630,309,000USD642,701,000USD536,059,999USD555,522,000USD30,403,000USD
    Non Current Liabilities Total136,057,000USD132,700,000USD404,634,000USD471,804,000USD478,316,000USD288,351,000USD87,428,000USD2,745,000USD
    Non Current Liabilities Other31,740,000USD22,373,000USD13,752,000USD10,278,000USD9,494,000USD7,029,000USD5,166,000USD2,745,000USD
    Non Currrent Assets Other21,859,000USD25,448,000USD21,325,000USD10,613,000USD9,108,000USD7,206,999USD14,975,000USD11,037,000USD
    Net Working Capital373,709,000USD374,667,000USD321,447,000USD371,500,000USD422,766,000USD419,740,000USD205,178,000USD146,202,000USD
    Unclassified Non Current Liabilities104,317,000USD110,327,000USD108,109,000USD162,584,000USD171,984,000USD74,365,000USD67,464,000USD-2,745,000USD
    Unclassified Equity1,585,866,000USD1,509,643,000USD1,059,570,000USD997,290,000USD952,385,000USD976,545,000USD861,696,000USD378,316,000USD
    Short Term Debt—2,474,000USD2,232,000USD430,000USD1,010,000USD1,185,000USD2,401,000USD—
    Unclassified Current Liabilities—-2,474,000USD-2,232,000USD———-1,559,000USD—
    Current Deferred Revenue——-1,309,000USD-430,000USD-1,010,000USD-1,185,000USD-2,401,000USD—
    Long Term Debt——282,773,000USD281,400,000USD280,026,000USD189,416,000USD——
    Other Liab———17,542,000USD16,812,000USD17,541,000USD14,798,000USD2,745,000USD
    Other Assets———17,691,000USD18,524,000USD88,225,000USD14,975,000USD11,250,000USD
    Net Tangible Assets———530,005,000USD188,236,000USD667,449,000USD673,272,000USD173,860,000USD
    Unclassified Non Current Assets———61,172,000USD70,021,000USD-78,659,000USD-14,975,000USD-11,037,000USD
    Treasury Stock————-132,000USD-132,000USD-132,000USD-132,000USD
    Unclassified Current Assets———————-4,124,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation20,667,000USD
    Stock Based Compensation48,009,000USD
    Change To Account Receivables-31,912,000USD
    Change To Inventory2,385,000USD
    Change To Liabilities2,195,000USD
    Change In Working Capital-27,625,000USD
    Operating Cash Flow2,297,000USD
    Capital Expenditures-6,697,000USD
    Net Investments15,782,000USD
    Other Investing Activities0USD
    Unclassified Investing Cash Flow-3,887,000USD
    Investing Cash Flow5,198,000USD
    Net Debt Issuance-640,000USD
    Net Common Stock Issuance-8,412,000USD
    Unclassified Financing Cash Flow25,812,000USD
    Financing Cash Flow16,760,000USD
    Effect Of Forex Changes On Cash-1,302,000USD
    Change In Cash22,953,000USD
    End Cash Flow117,600,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-19,783,000USD-133,657,000USD-16,231,000USD-19,657,000USD-18,146,000USD-33,580,000USD-21,409,000USD-50,545,000USD
    Depreciation11,797,000USD8,976,000USD10,188,000USD9,624,000USD9,305,000USD9,818,000USD10,061,000USD10,059,000USD
    Stock Based Compensation19,144,000USD17,300,000USD14,913,000USD18,019,000USD12,986,000USD13,309,000USD14,420,000USD11,313,000USD
    Other Non Cash Items149,000USD74,814,000USD-3,313,000USD6,047,000USD530,000USD9,280,000USD-1,884,000USD18,781,000USD
    Change To Account Receivables-12,459,000USD-10,244,000USD-18,792,000USD-11,668,000USD-12,316,000USD-5,490,000USD-4,462,000USD-4,660,000USD
    Change To Inventory832,000USD6,385,000USD659,000USD-2,731,000USD-1,668,000USD-627,000USD-3,056,000USD-6,554,000USD
    Change In Working Capital-23,833,000USD45,890,000USD-15,658,000USD-7,046,000USD-23,186,000USD1,895,000USD-10,775,000USD-7,975,000USD
    Total Cash From Operating Activities-12,526,000USD6,843,000USD-10,090,000USD6,979,000USD-18,521,000USD507,000USD-9,586,000USD-18,369,000USD
    Capital Expenditures-3,959,000USD-2,914,000USD-1,635,000USD-1,179,000USD-1,938,000USD-1,733,000USD-1,450,000USD-2,149,000USD
    Free Cash Flow-16,485,000USD3,929,000USD-11,725,000USD5,800,000USD-20,459,000USD-1,226,000USD-11,036,000USD-20,518,000USD
    Investments14,463,000USD-12,176,000USD-3,993,000USD-20,782,000USD-36,948,000USD11,787,000USD30,563,000USD34,864,000USD
    Total Cashflows From Investing Activities10,504,000USD-15,890,000USD-3,993,000USD-20,782,000USD-36,948,000USD11,787,000USD30,563,000USD34,864,000USD
    Net Borrowings-304,000USD-300,000USD-295,000USD-278,000USD-248,000USD-924,000USD-242,000USD—
    Total Cash From Financing Activities15,769,000USD2,427,000USD5,264,000USD2,245,000USD1,950,000USD60,113,000USD9,668,000USD8,592,000USD
    Change In Cash13,436,000USD-7,433,000USD-2,567,000USD-14,338,000USD-55,374,000USD69,483,000USD32,068,000USD25,580,000USD
    Begin Period Cash Flow94,647,000USD98,246,000USD100,813,000USD118,985,000USD169,626,000USD104,876,000USD68,075,000USD42,495,000USD
    End Period Cash Flow108,083,000USD90,813,000USD98,246,000USD104,647,000USD114,252,000USD174,359,000USD100,143,000USD68,075,000USD
    Other Cashflows From Investing Activities-759,000USD12,032,000USD-1,535,000USD-31,509,000USD-1,145,000USD76,000USD-1,146,000USD-1,036,000USD
    Other Cashflows From Financing Activities-5,638,000USD19,829,000USD-649,000USD-2,449,000USD-4,845,000USD51,199,000USD-328,000USD-2,127,000USD
    Unclassified Financing Cash Flow21,711,000USD-17,102,000USD6,208,000USD4,972,000USD7,043,000USD9,838,000USD8,111,000USD12,846,000USD
    Unclassified Operating Cash Flow—-6,480,000USD——————
    Unclassified Investing Cash Flow—-12,832,000USD3,170,000USD32,688,000USD3,083,000USD1,657,000USD2,596,000USD3,185,000USD
    Sale Purchase Of Stock——————2,127,000USD-2,127,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income-133,657,000USD-146,372,000USD-134,661,000USD-99,195,000USD-49,593,000USD-120,348,000USD15,424,000USD-12,951,000USD
    Depreciation38,093,000USD39,922,000USD37,978,000USD35,946,000USD34,421,000USD34,613,000USD9,863,000USD6,264,000USD
    Stock Based Compensation63,218,000USD50,207,000USD43,528,000USD38,561,000USD30,146,000USD46,477,000USD36,393,000USD25,704,000USD
    Other Non Cash Items24,044,000USD34,615,000USD5,650,000USD5,107,000USD7,186,000USD31,670,000USD45,119,000USD1,919,000USD
    Change To Account Receivables-53,020,000USD-21,966,000USD-3,843,000USD-3,138,000USD1,700,000USD2,243,000USD-6,632,000USD-2,252,000USD
    Change To Inventory2,645,000USD-18,788,000USD-4,830,000USD-15,472,000USD-7,703,000USD1,962,000USD4,078,000USD-2,303,000USD
    Change In Working Capital-31,551,000USD-39,474,000USD-10,133,000USD-13,448,000USD3,577,000USD-3,224,000USD-4,469,000USD-3,580,000USD
    Total Cash From Operating Activities-46,340,000USD-61,318,000USD-57,758,000USD-33,083,000USD24,708,000USD-22,988,000USD-369,000USD18,864,000USD
    Capital Expenditures-7,666,000USD-6,300,000USD-20,248,000USD-30,265,000USD-47,785,000USD-6,935,000USD-4,723,999USD-10,315,000USD
    Free Cash Flow-54,006,000USD-67,618,000USD-78,006,000USD-63,348,000USD-23,077,000USD-29,923,000USD-5,093,000USD8,549,000USD
    Investments-35,353,000USD47,831,000USD43,671,000USD75,901,000USD-8,369,000USD-196,305,000USD106,000USD-14,845,000USD
    Total Cashflows From Investing Activities-77,613,000USD47,831,000USD14,095,000USD44,779,000USD-58,232,000USD-205,060,000USD43,426,000USD-26,400,000USD
    Net Borrowings-1,121,000USD-1,589,000USD-711,000USD-527,000USD-659,000USD277,886,000USD-22,496,000USD-22,496,000USD
    Total Cash From Financing Activities11,886,000USD91,540,000USD15,042,000USD6,251,000USD39,260,000USD262,541,999USD-9,645,000USD21,576,000USD
    Change In Cash-111,263,000USD76,159,000USD-26,058,000USD18,817,000USD4,112,000USD34,166,000USD32,609,000USD14,088,000USD
    Begin Period Cash Flow174,359,000USD93,467,000USD119,525,000USD100,708,000USD96,596,000USD62,430,000USD29,821,000USD24,508,000USD
    End Period Cash Flow63,096,000USD169,626,000USD93,467,000USD119,525,000USD100,708,000USD96,596,000USD62,430,000USD38,596,000USD
    Other Cashflows From Investing Activities-22,157,000USD-3,151,000USD-3,170,000USD-1,008,000USD-2,081,000USD-1,820,000USD-1,608,000USD-1,240,000USD
    Other Cashflows From Financing Activities-8,132,000USD-6,563,000USD-3,273,000USD-2,429,000USD8,978,000USD-3,886,000USD-5,601,000USD21,576,000USD
    Unclassified Operating Cash Flow-6,487,000USD———-1,029,000USD-12,176,000USD-102,699,000USD1,508,000USD
    Unclassified Investing Cash Flow-12,437,000USD9,451,000USD-6,158,000USD———49,651,999USD—
    Unclassified Financing Cash Flow21,139,000USD106,255,000USD22,299,000USD18,414,000USD61,882,000USD254,969,999USD36,904,000USD23,083,000USD
    Sale Purchase Of Stock—-6,563,000USD-3,273,000USD-2,730,000USD-3,690,000USD-3,886,000USD-5,601,000USD-587,000USD
    Change To Liabilities———7,210,000USD12,448,000USD-2,683,000USD779,000USD2,527,000USD
    Dividends Paid———-6,477,000USD-27,251,000USD-262,542,000USD-12,851,000USD—
    Cash And Cash Equivalents Changes———17,947,000USD3,962,000USD34,406,000USD33,160,000USD14,088,000USD
    Exchange Rate Changes————-1,774,000USD-88,000USD-252,000USD48,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30GeographyInternational38,871,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30GeographyUnited States146,739,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductCorneal Health30,430,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductGlaucoma155,180,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31GeographyInternational38,227,000USD0001193125-26-193004
    Q1 2026Quarterly · 2026-03-31GeographyUnited States112,344,000USD0001193125-26-193004
    Q1 2026Quarterly · 2026-03-31ProductCorneal Health21,310,000USD0001193125-26-193004
    Q1 2026Quarterly · 2026-03-31ProductGlaucoma129,261,000USD0001193125-26-193004
    Q4 2025Quarterly · 2025-12-31GeographyInternational35,119,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31GeographyUnited States108,002,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductCorneal Health23,970,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductGlaucoma119,151,000USDLegacy provider
    FY 2025Yearly · 2025-12-31GeographyInternational132,400,000USD0001193125-26-061944
    FY 2025Yearly · 2025-12-31GeographyUnited States375,042,000USD0001193125-26-061944
    FY 2025Yearly · 2025-12-31ProductCorneal Health86,372,000USD0001193125-26-061944
    FY 2025Yearly · 2025-12-31ProductGlaucoma421,070,000USD0001193125-26-061944
    Q3 2025Quarterly · 2025-09-30GeographyInternational32,086,000USD0001104659-25-104529
    Q3 2025Quarterly · 2025-09-30GeographyUnited States101,451,000USD0001104659-25-104529
    Q3 2025Quarterly · 2025-09-30ProductCorneal Health23,288,000USD0001104659-25-104529
    Q3 2025Quarterly · 2025-09-30ProductGlaucoma110,249,000USD0001104659-25-104529
    Q2 2025Quarterly · 2025-06-30GeographyInternational33,601,000USD0001558370-25-010113
    Q2 2025Quarterly · 2025-06-30GeographyUnited States90,519,000USD0001558370-25-010113
    Q2 2025Quarterly · 2025-06-30ProductCorneal Health20,587,000USD0001558370-25-010113
    Q2 2025Quarterly · 2025-06-30ProductGlaucoma103,533,000USD0001558370-25-010113
    Q1 2025Quarterly · 2025-03-31GeographyInternational31,594,000USD0001193125-26-193004
    Q1 2025Quarterly · 2025-03-31GeographyUnited States75,070,000USD0001193125-26-193004
    Q1 2025Quarterly · 2025-03-31ProductCorneal Health18,527,000USD0001193125-26-193004
    Q1 2025Quarterly · 2025-03-31ProductGlaucoma88,137,000USD0001193125-26-193004
    Q4 2024Quarterly · 2024-12-31GeographyInternational29,930,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31GeographyUnited States75,569,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductCorneal Health21,356,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductGlaucoma84,143,000USDLegacy provider
    FY 2024Yearly · 2024-12-31GeographyInternational113,387,000USD0001193125-26-061944
    FY 2024Yearly · 2024-12-31GeographyUnited States270,094,000USD0001193125-26-061944
    FY 2024Yearly · 2024-12-31ProductCorneal Health80,205,000USD0001193125-26-061944
    FY 2024Yearly · 2024-12-31ProductGlaucoma303,276,000USD0001193125-26-061944
    Q3 2024Quarterly · 2024-09-30GeographyInternational26,653,000USD0001104659-25-104529
    Q3 2024Quarterly · 2024-09-30GeographyUnited States70,017,000USD0001104659-25-104529
    Q3 2024Quarterly · 2024-09-30ProductCorneal Health20,638,000USD0001104659-25-104529
    Q3 2024Quarterly · 2024-09-30ProductGlaucoma76,032,000USD0001104659-25-104529
    FY 2023Yearly · 2023-12-31GeographyInternational95,315,000USD0001193125-26-061944
    FY 2023Yearly · 2023-12-31GeographyUnited States219,396,000USD0001193125-26-061944
    FY 2023Yearly · 2023-12-31ProductCorneal Health77,672,000USD0001193125-26-061944
    FY 2023Yearly · 2023-12-31ProductGlaucoma237,039,000USD0001193125-26-061944
    FY 2022Yearly · 2022-12-31GeographyInternational79,624,000USD0001558370-25-001402
    FY 2022Yearly · 2022-12-31GeographyUnited States203,238,000USD0001558370-25-001402
    FY 2022Yearly · 2022-12-31ProductCorneal Health68,624,000USD0001558370-25-001402
    FY 2022Yearly · 2022-12-31ProductGlaucoma214,238,000USD0001558370-25-001402
    FY 2021Yearly · 2021-12-31GeographyInternational70,220,000USD0001558370-24-001630
    FY 2021Yearly · 2021-12-31GeographyUnited States223,791,000USD0001558370-24-001630
    FY 2021Yearly · 2021-12-31ProductCorneal Health62,034,000USD0001558370-24-001630
    FY 2021Yearly · 2021-12-31ProductGlaucoma231,977,000USD0001558370-24-001630
    FY 2020Yearly · 2020-12-31GeographyInternational51,873,000USD0001558370-23-002070
    FY 2020Yearly · 2020-12-31GeographyUnited States173,086,000USD0001558370-23-002070
    FY 2020Yearly · 2020-12-31ProductCorneal Health45,596,000USD0001558370-23-002070
    FY 2020Yearly · 2020-12-31ProductGlaucoma179,363,000USD0001558370-23-002070
    FY 2019Yearly · 2019-12-31GeographyInternational44,528,000USD0001558370-22-002371
    FY 2019Yearly · 2019-12-31GeographyUnited States192,456,000USD0001558370-22-002371
    FY 2019Yearly · 2019-12-31ProductCorneal Health6,017,000USD0001558370-22-002371
    FY 2019Yearly · 2019-12-31ProductGlaucoma230,967,000USD0001558370-22-002371
    FY 2018Yearly · 2018-12-31GeographyInternational29,601,000USD0001558370-21-002061
    FY 2018Yearly · 2018-12-31GeographyUnited States151,677,000USD0001558370-21-002061

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.